A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients with Heart Failure with Reduced Ejection Fraction

TY - JOUR

T1 - A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients with Heart Failure with Reduced Ejection Fraction

AU - Kim, Daniel S.

AU - Dau, Nhu Quyen

AU - Peled, Harry

N1 - Funding Information: Conflict of Interest Disclosures: Dr Singal reported receiving personal fees from Gilead Pharmaceuticals and the American College of Gastroenterology, nonfinancial support from the American Association for the Study of Liver Diseases, and grants from the American College of Gastroenterology and National Institute on Alcohol Abuse and Alcoholism during the conduct of the study, as well as grants from the National Institute of Diabetes and Digestive and Kidney Diseases; personal fees from Gilead Pharmaceuticals, Recordati Pharmaceuticals, Alnylam Pharmaceuticals, Medscape Gastroenterology, the Chronic Liver Disease Foundation, and UpToDate; and nonfinancial support from the American Porphyria Foundation outside the submitted work. Dr Mathurin reported receiving personal fees from Gilead and Verlyx during the conduct of the study and personal fees from Bayer Healthcare, AbbVie, Ipsen, Eisai, Merck, Sharp & Dohme, Servier, and Sanofi outside the submitted work. Funding Information: Conflict of Interest Disclosures: Dr DeVore reported receiving research funding from AstraZeneca, Amgen, the American Heart Association, Bayer, Luitpold Pharmaceuticals, the National Heart, Lung, and Blood Institute, the Patient-Centered Outcomes Research Institute, and Novartis and consulting for AstraZeneca, Mardil Medical, Novartis, and Procyrion. Dr Hernandez reported receiving research funding from American Regent, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Verily and consulting for AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Merck, Myokardia, and Novartis. No other disclosures were reported. 1. DeVore AD, Granger BB, Fonarow GC, et al. Effect of a hospital and postdischarge quality improvement intervention on clinical outcomes and quality of care for patients with heart failure with reduced ejection fraction: the CONNECT-HF randomized clinical trial. JAMA. 2021;326(4):314-323. doi:10. 1001/jama.2021.8844 2. DeVore AD, Granger BB, Fonarow GC, et al. Care optimization through patient and hospital engagement clinical trial for heart failure: rationale and design of CONNECT-HF. Am Heart J. 2020;220:41-50. doi:10.1016/j.ahj.2019. 09.012

PY - 2021/11/16

Y1 - 2021/11/16

UR - https://www.scopus.com/pages/publications/85119365244

U2 - 10.1001/jama.2021.16753

DO - 10.1001/jama.2021.16753

M3 - Letter

C2 - 34783843

AN - SCOPUS:85119365244

SN - 0098-7484

VL - 326

SP - 1976

EP - 1977

JO - JAMA: The Journal of the American Medical Association

JF - JAMA: The Journal of the American Medical Association

IS - 19

ER -